Research archive for AMGN

Amgen is one of our less flashy holdings. Can I say boring? Sometimes boring is good. Last week, they released solid results. Fourth quarter revenues were up 11%. Ten products in their pipeline managed double-digit growth, including their blockbuster cholesterol drug Repatha which grew by a whopping 45%.

Last week, Amgen fell 5% after publishing data on a phase 2 study of MariTide, its weight-loss drug. Over a year, patients lost on average 20% of their weight, slightly quicker than competitors. There was a concern that around 50% of patients reported nausea after the first dose, with 20% vomiting. After the first dose, the nausea mostly subsides.

Vestact-recommended biotech company Amgen had results out two weeks ago. The stock has been okay this year, up 9%, but has underperformed the broader market. All the complicated drug names can make writing about their results boring, but I'll do my best to keep things simple for the 617 clients that own the share.

Vestact-recommended biopharma company Amgen had second quarter results out on Tuesday. They were largely in line with market expectations, other than a very modest shortfall on profits. They made $4.97 per share instead of $5.00, I kid you not.

Amgen reported strong results last week. Its shares closed up over 10% on the day after its CEO expressed optimism about early trial results for its obesity drug, MariTide.

We are entering a golden age for biotech companies and Vestact-recommended stock Amgen is not being left behind. There are three major innovations in progress now: (1) advancements in AI and deep learning, (2) significant cost reductions for collecting biological data through lab automation, and (3) the precision editing of DNA with CRISPR.

Amgen's results from last week weren't as exciting as Eli Lilly's, but were still decent, with revenue and profit both higher than analyst expectations. Revenue was up 7% for the full-year, driven by record sales for 18 of their brands. We like Amgen because it isn't a one-trick pony.

Amgen is our favoured biotech pharma stock. The company released results this week and it's my job to unpack them for you.

Amgen reported good earnings thanks to strong sales of its treatments for cholesterol, osteoporosis, and other drugs. This biotech pharma company is a Vestact-recommended stock. Revenue for the quarter reached $6.99 billion, up 6%, and earnings per share rose to $5, surpassing analysts' expectations.

The Federal Trade Commission (FTC) is attempting to block Amgen's $27.8 billion purchase of Horizon Therapeutics. In their view the deal would stifle competition and delay the development of new treatments. Horizon has a near-monopoly on medications for eye thyroid disease and refractory gout. Amgen might increase drug prices to get a return on their huge investment.

Amgen reported results which were mostly in line with what the market was expecting. The company increased the volume of drugs sold, but due to a strong Dollar and their changing sales mix, revenue dropped 2%.

Here is a bit more information about Amgen's Humira biosimilar (generic) called Amjevita. Humira is an inflammation drug used to target pain associated with rheumatoid arthritis and a condition called spondylitis.

Amgen is a biopharmaceutical giant that was established in California in 1980, and has been a Vestact-recommended stock since 2015. It has a wide variety of drugs in production and a tremendous team of researchers working on new medicines.

Amgen has been one of our top-performing stocks this year. The drug company has strong cash flow and scored a win with early trials showing positive data for their anti-obesity drug. Amgen are now in advanced talks to buy drug company Horizon Therapeutics in a deal likely to be valued well over $20 billion, marking the largest healthcare merger of the year. The Vestact-recommended company is the last of three suitors standing in an auction for Horizon after Sanofi and J&J capitulated.

Vestact-recommended stock Amgen released its third-quarter earnings last week which beat both on earnings and revenue. This sent shares higher, bringing the total year-to-date returns to above 29%. That's very impressive, given that the overall S&P 500 index is down 20% for 2022.